2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
416
Lymphoma
406
Lymphoma, Non-Hodgkin
344
Leukemia, Lymphocytic, Chronic, B-Cell
313
Lymphoma, Follicular
301
Lymphoma, Mantle-Cell
226
Lymphoma, B-Cell, Marginal Zone
161
Leukemia
119
Lymphoma, B-Cell
112
Burkitt Lymphoma
110
Waldenstrom Macroglobulinemia
99
Precursor Cell Lymphoblastic Leukemia-Lymphoma
90
Recurrence
85
Hodgkin Disease
60
Lymphoma, Large-Cell, Immunoblastic
57
Neoplasms
39
Multiple Myeloma
26
Lymphoma, Large-Cell, Anaplastic
26
Myelodysplastic Syndromes
25
Leukemia, Myeloid, Acute
24
Hematologic Neoplasms
22
Dendritic Cell Sarcoma, Interdigitating
22
Leukemia, Hairy Cell
20
Intraocular Lymphoma
17
Leukemia, Prolymphocytic
16
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, T-Cell
14
Neoplasms, Plasma Cell
13
Hematologic Diseases
13
Lymphoproliferative Disorders
12
Interventions
Fulvestrant
10
Alpelisib
7
Everolimus
6
Cetuximab
6
Letrozole
4
serabelisib
3
ribociclib
3
pembrolizumab
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
NVP-BKM120
3
Irinotecan
3
sapanisertib
2
parsaclisib
2
olaparib
2
binimetinib
2
Topotecan
2
Gemcitabine
2
Carboplatin
2
volagidemab
1
venetoclax
1
tivozanib
1
tipifarnib
1
tanezumab
1
talazoparib
1
sotorasib
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Rituximab
×
Clear all
NCT02204982
2023-09-28
DYNAMO + R
SecuraBio
Phase 3
Terminated
13 enrolled
10 charts
1 FDA